Corruption of Cong by Pharma: Greenwood offered job / drops Pharma hearing Tue, 20 Jul 2004 Related link: Cong Greenwood’s version Big Pharma buys a congressman and derails a public hearing focusing on pharmaceutical company concealment of evidence showing antidepressants increase risks of harm and show no benefit for children…
WSJ: Debate Over Antidepressants: FDA role in suppressing damaging data Tue, 25 May 2004 How were drug manufacturers able to conceal vital evidence of harmful antidepressant drug effects? The answer is becoming clearer by the day: federal regulators and the psychiatrists who tested these drugs in clinical trials are invested…
Prescription for Suicide? TIME MAGAZINE Fri, 6 Feb 2004 TIME magazine asks whether antidepressants are a Prescription for Suicide. Shannon Baker, whose 12 year old daughter, Kara Jaye-Anne Otter, committed suicide when she had been on the antidepressant Paxil for seven months, recalls: “I was told the worst side effects…
NYSOMH Issues Alerts, Guidelines re Antidepressant Use in Children, Teens Wed, 29 Dec 2004 The NYS Office of Mental Health has issued letters and an advisory to state mental health providers “explaining” FDA’s warning and the use of antidepressants in children. As you will note, OMH downplays the meaning of…
FDA Foot Dragging – Three Months After Expert Panel Urged “Black Box” Warnings for Antidepressants, No Action Thu, 23 Dec 2004 Why is the FDA failing to enforce the "Black Box" warnings on SSRI antidepressant drug labels? When questioned by the NJ Star Ledger, Robert Temple, director of the FDA’s…
NY Times Does it Again – Drug Advertisers Get Front Page Coverage to Boost SSRI Market Wed, 2 Jun 2004 The New York Times saw fit to print a report about preliminary, unpublished findings of a study whose authors claim to have “found that Prozac helps teenagers overcome depression far…
Conflicts of Interest policy – New York Times Sun, 28 Mar 2004 To: ‘Executive-editor@nytimes’; ‘gcollins@nytimes’; ‘arosenthal@nytimes’; ‘pboffey@nytimes’; ‘lchang@nytimes’; ‘oped@nytimes’ Cc: ‘Daniel Okrent’ ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure https://ahrp.org FYI Friday’s New York Times included the following Editor’s Note on the paper’s Op Ed page:…
Take Action: Just Say No to Stigmatizing Screening and Unsafe Drugs Tue, 26 Oct 2004 FYI /ACTION! AHRP believes that America’s school children should not be screened and labeled without a guarantee of the proven accuracy of the screening tool, and the proven safety and therapeutic value of the treatment…
Three Questionable FDA policies: drug factory inspection rules/ clinical trials/ Paxil ads Thu, 22 Aug 2002 Three news items highlight questionable FDA policies that are in conflict with consumer health interests. 1) Poor quality control standards in American drug and vaccine manufacturing plants is a disgrace. The Associated Press reports…
Research Protection: SCIENCE / Fed Paper Mon, 28 Oct 2002 SCIENCE magazine (below) reported about “the bumpy road” of Dr. Greg Koski’s tenure as director of the federal Office of Human Research Protections (OHRP), and how his resignation is being perceived by some. An article in The FEDERAL PAPER focused…
FDA Approves Lilly’s Growth Hormone for Healthy Children Mon, 28 Jul 2003 The FDA has approved Eli Lilly’s injectable human growth hormone (hGH) therapy, Humatrope, for healthy children who are short but have no hormonal deficiency. Lilly claims that its trials in 300 healthy short children resulted in an increase…
Analysis of paroxetine Yellow Card adverse drug reaction reports (Seroxat/Paxil) Thu, 20 Nov 2003 A unique analysis of the British Yellow Card Reporting system for adverse drug reactions (ADR) found that the nature, the scope and severity of ADRs relating to drug dependency and suicidal behavior from the antidepressant paroxetine…
